Israel-based IceCure Medical (NASDAQ: ICCM) has announced that it has obtained regulatory approval from China’s National Medical Product Administration (NMPA) for the commercial launch of its IceSense3 disposable cryoprobes product and its accompanying product console. This minimally-invasive cryoablation technology utilizes liquid nitrogen to freeze and destroy tumors, offering a treatment option for both malignant and benign growths in various tissues, including the breast, lung, bone, liver, and kidneys, as well as in palliative care settings.
Distribution Partnerships in China
IceCure’s product will be distributed in China through strategic partnerships with Shanghai Medtronic Zhikang Medical Devices Co., Ltd, an affiliate of Medtronic plc, and Beijing Turing Medical Technology Co., Ltd. This expansion into the Chinese market follows the global marketing of IceCure’s product in countries such as the United States and across the European Union.
Global Reach and Impact of IceCure’s Cryoablation Technology
The approval from the NMPA is a significant milestone for IceCure Medical, as it broadens the company’s global reach and impact. The IceSense3 cryoprobes provide a minimally-invasive alternative for tumor treatment, which is particularly beneficial for patients with conditions affecting hard-to-reach areas or those who are not suitable candidates for more invasive procedures.-Fineline Info & Tech
